Equities research analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report earnings of ($0.13) per share for the current quarter, Zacks reports. Four analysts have made estimates for BioDelivery Sciences International’s earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.10). BioDelivery Sciences International posted earnings per share of ($0.21) during the same quarter last year, which suggests a positive year-over-year growth rate of 38.1%. The company is scheduled to announce its next earnings results on Thursday, November 8th.

On average, analysts expect that BioDelivery Sciences International will report full year earnings of ($0.62) per share for the current year, with EPS estimates ranging from ($0.73) to ($0.51). For the next year, analysts forecast that the firm will post earnings of ($0.38) per share, with EPS estimates ranging from ($0.63) to ($0.19). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for BioDelivery Sciences International.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The company had revenue of $12.18 million for the quarter, compared to the consensus estimate of $12.44 million. BioDelivery Sciences International had a negative return on equity of 278.79% and a negative net margin of 103.01%.

A number of research firms have commented on BDSI. Zacks Investment Research cut BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday. HC Wainwright set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Monday, October 8th. Finally, Cantor Fitzgerald set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a report on Sunday, October 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. BioDelivery Sciences International presently has an average rating of “Buy” and an average target price of $4.38.

NASDAQ:BDSI traded up $0.03 on Tuesday, reaching $3.75. 1,360,900 shares of the company’s stock traded hands, compared to its average volume of 467,682. The company has a quick ratio of 2.90, a current ratio of 3.16 and a debt-to-equity ratio of 1.21. The stock has a market cap of $166.77 million, a PE ratio of -9.87 and a beta of 0.63. BioDelivery Sciences International has a 12 month low of $1.70 and a 12 month high of $3.90.

In other news, Director Francis E. Odonnell, Jr. sold 151,039 shares of BioDelivery Sciences International stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $2.84, for a total value of $428,950.76. Following the sale, the director now directly owns 520,482 shares of the company’s stock, valued at $1,478,168.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 167,039 shares of company stock worth $473,271 over the last ninety days. Insiders own 13.26% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its holdings in shares of BioDelivery Sciences International by 2.7% in the second quarter. BlackRock Inc. now owns 1,190,286 shares of the specialty pharmaceutical company’s stock worth $3,512,000 after purchasing an additional 30,991 shares during the last quarter. Northern Trust Corp grew its position in BioDelivery Sciences International by 19.9% in the second quarter. Northern Trust Corp now owns 191,016 shares of the specialty pharmaceutical company’s stock worth $563,000 after acquiring an additional 31,749 shares in the last quarter. Bank of Montreal Can purchased a new position in BioDelivery Sciences International in the second quarter worth about $138,000. PNC Financial Services Group Inc. purchased a new position in BioDelivery Sciences International in the second quarter worth about $148,000. Finally, GSA Capital Partners LLP grew its position in BioDelivery Sciences International by 12.7% in the first quarter. GSA Capital Partners LLP now owns 460,567 shares of the specialty pharmaceutical company’s stock worth $1,036,000 after acquiring an additional 51,900 shares in the last quarter. 45.46% of the stock is currently owned by hedge funds and other institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

See Also: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.